Dr. Andrew Pollard, an expert in pediatric infection and immunity at Oxford, said research was slowed by low infection rates over the summer, but the Phase III trials are now accumulating the data needed to report results as a renewed surge of the pandemic hits countries around the world. Oxford is developing its vaccine in conjunction with the drugmaker AstraZeneca. “I think we’re getting close, and it’s definitely going to be before Christmas based on the progress,” Pollard said in an interview with the BBC.
Pollard discussed progress in the late-stage trials as Oxford released a study based on earlier research that found the vaccine was well tolerated and produced a strong immune response in people over 70. This is important because vaccines often don’t work as well in older people, Pollard said. “The reason that we’re so delighted is the we’re seeing the immune responses look exactly the same, even in those who are over 70 years of age,” Pollard said.
https://apnews.com/article/internat...rus-pandemic-5aaadfba89552363fbbf58b7a599105f
Perhaps announce results in 2-4-weeks.
Pollard discussed progress in the late-stage trials as Oxford released a study based on earlier research that found the vaccine was well tolerated and produced a strong immune response in people over 70. This is important because vaccines often don’t work as well in older people, Pollard said. “The reason that we’re so delighted is the we’re seeing the immune responses look exactly the same, even in those who are over 70 years of age,” Pollard said.
https://apnews.com/article/internat...rus-pandemic-5aaadfba89552363fbbf58b7a599105f
Perhaps announce results in 2-4-weeks.
